Founded in 2005, Androbiosys, Inc. is a biotechnology firm dedicated to the research and development of treatments for prostate diseases. The company's core mission is to advance medical science in the field of urology through innovative biological and physical research. Androbiosys offers a range of commercial R&D services, focusing on developing effective therapies for prostate-related conditions. Their market focus includes healthcare providers, medical researchers, and pharmaceutical companies seeking specialized expertise in prostate disease treatments.
Notable figures associated with Androbiosys include leading scientists and medical researchers in the field of urology. The company has attracted investment from prominent biotech venture capital firms, underscoring its potential and credibility in the industry. Key achievements include several breakthroughs in prostate disease treatment methodologies and successful collaborations with major healthcare institutions. Overall, Androbiosys has made a significant impact by contributing valuable research and innovative solutions to improve patient outcomes in prostate health.
Quick Facts
When was Androbiosys' last funding round?
Androbiosys' most recent funding round was for $500k (USD) in January 2009.
How much disclosed funding has Androbiosys raised?
As of Jan 9, 2009, Androbiosys has disclosed funding of $500k (USD).